RxDoctor Payments Data

Megan Cowsill, DO

Ophthalmology · Saint Clair Shores, MINPI 1689792228

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $20,498 of the $21,225 with a category attached, or 96.6%. Baxter Healthcare accounts for 96.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $13,184 and has fallen 99.7% since, to $40 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,225in general payments, 2019–2025

Across 53 payments — averaging $400.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$20K
  • AbbVie$371
  • Amgen$77
  • Tarsus Pharmaceuticals, Inc.$65
  • Novartis$51
  • Mallinckrodt Hospital Products Inc.$44
  • plus $120 from 6 others

What the payments were for

  • Consulting fees$20,49897%
  • Food & beverage$6083%
  • Education$800%
  • Gifts$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,225 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$25,808
Medicare patients
87
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost67$30,497
RestasisCyclosporine13$10,443
Brimonidine Tartrate46$9,774
Timolol Maleate39$2,424
Latanoprost85$1,095
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$732
Prednisolone Acetate15$673
Tobramycin-DexamethasoneTobramycin/Dexamethasone13$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$371$40,93980 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Saint Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →